Researchers at Gladstone Institutes published multiomic analyses in Immunity identifying cell‑intrinsic and extrinsic mechanisms tied to post‑treatment HIV control and reported that metformin activates a gene linked to prolonged viral suppression after ART interruption. The study analyzed ART‑interruption cohorts and pinpointed two genes acting as 'locks' that keep HIV dormant in infected cells. Lead investigator Nadia Roan and colleagues showed metformin can engage one of these pathways in preclinical models, suggesting the drug might delay viral rebound in some patients. The authors called for preclinical and clinical studies to test metformin’s potential adjunctive role in remission strategies. The findings open a translational research path using an inexpensive, widely used drug to modulate reservoir biology; next steps include controlled trials to assess whether metformin‑driven mechanisms yield clinically meaningful delays in rebound across diverse patient populations.